We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
非小细胞肺癌患者免疫检查点抑制剂相关性肺炎与免疫检查点抑制剂 疗效相关性分析
- Authors
陈翔; 加冷; 热哈提汗; 顾国民; 阿布地力; 阿布都许库; 莎毕娜; 迪力夏提; 杨喆; 王海峰
- Abstract
Objective: To investigate the relationship between the incidence of immune checkpoint inhibitor-associated pneumonia (CIP) and the efficacy of immunotherapy in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), and to explore the prognostic factors of patients receiving ICI treatment. Methods: The clinical and follow-up data of 145 NSCLC patients treated with ICIs in the Affiliated Cancer Hospital of Xinjiang Medical University from March 2020 to March 2023 were retrospectively analyzed. The patients were divided into CIP group and non-CIP group. The patients with CIP were sub-divided into mild (grade 1, 2) and severe (grade 3, 4) CIP subgroups. The effects of the occurrence and severity of CIP on the overall survival (OS) time and progression-free survival (PFS) time of the patients were analyzed by comparing the survival curve using Kaplan-Meier method. Univariate and multivariate COX proportional hazard regression models were used to analyze the prognostic factors associated with PFS and OS. Results: A total of 26 patients developed CIP, with an incidence rate of 17.93% (26/145), and the incidence of severe CIP was 3.4%. The PFS in CIP group was significantly longer than that in non-CIP group (12.3 vs 7.6 months, P<0.05). There was no significant difference in OS between CIP group and non-CIP group (16.2 vs 15.8 months, P>0.05). Subgroup analysis showed that there were no significant differences in PFS (12.2 vs 12.9 months) and OS (16.1 vs 17.8 months) between mild CIP and severe CIP groups (all P>0.05). Multivariate COX regression analysis showed that CIP (HR=0.55, 95%CI [0.33,0.90], P=0.02) and the course of immunotherapy >6 cycles (HR=0.51, 95%CI [0.31, 0.85], P=0.01) were favorable prognostic factors for PFS. The course of immunotherapy >6 cycles (HR=0.4, 95%CI [0.18,0.88], P=0.02) was a favorable prognostic factor for OS. Conclusion: The incidence of CIP is 17.93%. The occurrence of CIP is closely related to the prolongation of PFS. Immunotherapy course >6 cycles is a favorable prognostic factor for PFS and OS of NSCLC patients.
- Subjects
CHINA; RISK factors of pneumonia; LUNG cancer; PNEUMONIA; DRUG efficacy; IMMUNE checkpoint inhibitors; ACADEMIC medical centers; CONFIDENCE intervals; MULTIPLE regression analysis; RETROSPECTIVE studies; DISEASE incidence; RISK assessment; CANCER patients; COMPARATIVE studies; SEVERITY of illness index; DESCRIPTIVE statistics; SURVIVAL analysis (Biometry); KAPLAN-Meier estimator; PROGRESSION-free survival; IMMUNOTHERAPY; OVERALL survival; PROPORTIONAL hazards models
- Publication
Chinese Journal of Cancer Biotherapy, 2024, Vol 31, Issue 1, p54
- ISSN
1007-385X
- Publication type
Article
- DOI
10.3872/j.issn.1007-385x.2024.01.008